Company registration number 07472363 (England and Wales)
FAIRVIEW PHARMACY LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
PAGES FOR FILING WITH REGISTRAR
FAIRVIEW PHARMACY LIMITED
CONTENTS
Page
Statement of financial position
1
Notes to the financial statements
2 - 7
FAIRVIEW PHARMACY LIMITED
STATEMENT OF FINANCIAL POSITION
AS AT
31 DECEMBER 2024
31 December 2024
- 1 -
2024
2023
Notes
£
£
£
£
Current assets
Stocks
80,955
78,416
Debtors
5
181,110
170,370
Cash at bank and in hand
337,092
162,611
599,157
411,397
Creditors: amounts falling due within one year
6
(359,080)
(294,395)
Net current assets
240,077
117,002
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
239,977
116,902
Total equity
240,077
117,002

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the income statement within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 29 September 2025 and are signed on its behalf by:
J Merali
Director
Company registration number 07472363 (England and Wales)
FAIRVIEW PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 2 -
1
Accounting policies
Company information

Fairview Pharmacy Limited is a private company limited by shares incorporated in England and Wales. The registered office is 3 Hobbs House, Harrovian Business Village, Bessborough Road, Harrow, Middlesex, HA1 3EX.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

This company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements:

 

 

The financial statements of the company are consolidated in the financial statements of The Fairview Group (UK) Limited. These consolidated financial statements are available from the Registrar of Companies.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

The company recognises revenue from the following major sources:

The nature, timing of satisfaction of performance obligations and significant payment terms of the company's major sources of revenue are as follows:

FAIRVIEW PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 3 -
Sales of goods and services

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that are recoverable.

Other fees receivable

Other fees receivable are recognised when it is probable that the economic benefits will flow to the company and the amount of revenue can be measured reliably.

Other income

Other income is recognised when it is probable that the economic benefits will flow to the company and the amount of revenue can be measured reliably.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
20% per annum straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.5
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

FAIRVIEW PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 4 -
1.6
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.7
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.8
Taxation

The tax expense represents the sum of the tax currently payable and any deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

FAIRVIEW PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 5 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity.

1.9
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.10
Retirement benefits

The company operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the company in an independently administered fund. Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.11
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
13
12
FAIRVIEW PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 6 -
4
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 January 2024 and 31 December 2024
23,675
Depreciation and impairment
At 1 January 2024 and 31 December 2024
23,675
Carrying amount
At 31 December 2024
-
0
At 31 December 2023
-
0
5
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
105,745
125,585
Other debtors
75,365
44,785
181,110
170,370
6
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
170,888
193,122
Amounts owed to group undertakings
99,398
18,690
Corporation tax
42,303
33,912
Other taxation and social security
4,021
4,529
Other creditors
42,470
44,142
359,080
294,395
7
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified and includes the following:

FAIRVIEW PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
7
Audit report information
(Continued)
- 7 -
Opinion

In our opinion the financial statements:

Senior Statutory Auditor:
Mohamedkazim Bhaloo
Statutory Auditor:
Deitch Cooper LLP
Date of audit report:
29 September 2025
8
Related party transactions
Transactions with related parties

During the year the company entered into the following transactions with related parties:

 

During the year, the company paid rent of £19,853 (2023: £20,225) to the personal pension scheme of a Director.

 

During the year the company received income of £160,000 (2023: £105,000) from Edgware Hospital Pharmacy Limited, a company controlled by close family members of the Directors and with shareholders in common. Included within creditors are amounts due to Edgware Hospital Pharmacy Limited, a company controlled by the Directors, amounting to £10,000 (2023: £7,544).

Included within creditors are loans payable to Fairview Health Partnerships Limited, a company controlled by the Directors, amounting to £1,682 (2023: £8,682).

 

Included within debtors are loans to ASFA Holdings Ltd, a company in which J Merali is a Director and shareholder, amounting to £32,485 (2023: £Nil).

Other information

The company has taken advantage of the exemption available whereby it has not disclosed transactions entered into with the parent undertaking and other wholly owned subsidiaries of the group.

9
Directors' transactions

Included within creditors are amounts owed to Directors totalling £1,981 (2023: £2,633).

10
Parent company

The ultimate parent undertaking of Fairview Pharmacy Limited is The Fairview Group (UK) Limited and its registered office is 3 Hobbs House, Harrovian Business Village, Bessborough Road, Harrow, Middlesex, England, HA1 3EX.

The parent undertaking of the smallest and largest group of undertakings for which group accounts are drawn up of which the company is a member is The Fairview Group (UK) Limited.

2024-12-312024-01-01falsefalsefalse29 September 2025CCH SoftwareCCH Accounts Production 2025.200No description of principal activityJ MeraliR Esmail074723632024-01-012024-12-31074723632024-12-31074723632023-12-3107472363core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3107472363core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3107472363core:ShareCapital2024-12-3107472363core:ShareCapital2023-12-3107472363core:RetainedEarningsAccumulatedLosses2024-12-3107472363core:RetainedEarningsAccumulatedLosses2023-12-3107472363bus:Director12024-01-012024-12-3107472363core:FurnitureFittings2024-01-012024-12-31074723632023-01-012023-12-3107472363core:OtherPropertyPlantEquipment2023-12-3107472363core:OtherPropertyPlantEquipment2024-12-3107472363core:OtherPropertyPlantEquipment2023-12-3107472363core:CurrentFinancialInstruments2024-12-3107472363core:CurrentFinancialInstruments2023-12-3107472363core:WithinOneYear2024-12-3107472363core:WithinOneYear2023-12-3107472363bus:PrivateLimitedCompanyLtd2024-01-012024-12-3107472363bus:FRS1022024-01-012024-12-3107472363bus:Audited2024-01-012024-12-3107472363bus:Director22024-01-012024-12-3107472363bus:SmallCompaniesRegimeForAccounts2024-01-012024-12-3107472363bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP